Anti-TNF alpha-induced immune-mediated skin adverse reactions resolved by switching to ustekinumab

Czech version

Authors: Vorčáková K. ¹; Horáková M. ²; Péč J. ¹
Authors‘ workplace: Dermatovenerologická klinika JLF UK a UN Martin ¹; Gastroenterologická klinika JLF UK a UN Martin ²
Published in: Gastroent Hepatol 2019; 73(6): 496-500
Category:
doi: https://doi.org/10.14735/amgh2019469

Overview

Immune-mediated adverse reactions are a new group of conditions that develop during anti-TNF-alpha treatment. Their etiopathogenesis remains unclear. This study describes three forms of immune-mediated adverse reactions of the skin that were diagnosed correctly. Some types of immune-mediated adverse reactions, such as palmoplantar pustular psoriasis, may persist for a long time after switching biologic agents.

Submitted: 19. 9. 2019

Accepted: 17. 11. 2019

Conflict of Interest: The authors declare that the article/ manuscript complies with ethical standards, patient anonymity has been respected, and they state that they have no financial, advisory or other commercial interests in relation to the subject matter.

Publication Ethics: This article/ manuscript has not been published or is currently being submitted for another review. The authors agree to publish their name and e-mail in the published article/ manuscript.

Dedication: This manuscript was created with the support of Johnson & Johnson Ltd., Janssen Division, EM-18429.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for bio medical papers.

Keywords:

ustekinumab – cutaneous adverse effects – anti-TNF-alpha

Sources

1. Andrade P, Lopes S, Gaspar R et al. Anti-tumor necrosis factor-α-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci 2018; 63 (3): 746–54. doi: 10.1007/s10620-018-4921-y.

2. Verea MM, Del Pozo J, Yebra-Pimentel MT et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38 (1): 54–57. doi: 10.1345/aph.1C477.

3. Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatology 2018; 53: 49–63. doi: 10.1159/ 000479475.

4. Vorčáková K, Juraj P, Péčová T et al. Immune-mediated skin reactions induced by recombinant antibodies and other TNF-alpha inhibitors. [online]. Available from: https: //www.intechopen.com/books/antibody-engineering/immune-mediated-skin-reactions-induced-by-recombinant-antibodies-and-other-tnf-alpha-inhibitors.

5. Ciccarelli F, De Martinis M, Sirufo MM et al. Psoriasis induced by anti-tumor necrosis factor alpha agents: a comprehensive review of the literature. Acta Dermatovenerol Croat 2016; 24 (3): 169–174.

6. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40 (3): 233–240. doi: 10.1016/ j.semarthrit.2010.04.003.

7. Vinkel C, Thomsen SF. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. Int J Dermatol 2017; 56 (8): 811–818. doi: 10.1111/ijd.13603.

8. Vorcakova K, Pecova T, Turonova L. Anti-dsDNA antibodies and their association with paradoxical psoriasis induced by TNF alfa inhibitors. Bratislava Lek Listy 2017; 118 (4): 250–250. doi: 10.4149/BLL_2017_049.

9. Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol 2014; 10 (1): 159–169. doi: 10.1586/1744666X.2014.866038.